Ben Fransen
CEO, Expression Biotech
Replay available
ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q1 2026 Earnings Call
ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2) Q1 2026 earnings conference call, held 2026-05-28. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Keith Alexander
CFO, Expression Biotech
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Expres2ion Biotech Holding Ab.
Replay transcript excerpt
WEBVTT 00:00:01.972 -- 00:00:07.039 Welcome to today's event where we have the pleasure to present Expression Biotech. 00:00:07.039 -- 00:00:12.306 As you can see here on the front page the Q1 report is of course the reason 00:00:12.306 -- 00:00:16.031 for today and the main topic for today and of course the pipeline news. 00:00:16.031 -- 00:00:18.835 So it was through today's presentation I answer questions in the end. 00:00:18.835 -- 00:00:22.019 We are joined by CEO Ben Fransen and CFO Keith Alexander. 00:00:22.019 -- 00:00:24.963 As always, there's a box down below where you can ask questions. 00:00:24.963 -- 00:00:28.728 If you do it in Danish, I will try and translate to the best of my ability. 00:00:28.728 -- 00:00:33.635 We have a firm stop at 10.30, so I will catch as many questions as possible. 00:00:33.635 -- 00:00:37.478 But we have a firm stop at 10.30. 00:00:37.821 -- 00:00:43.106 So I will not take any more time and leave the word over to you, Bent. 00:00:43.549 -- 00:00:46.533 Thank you, Michael. And good morning, everyone. 00:00:46.533 -- 00:00:49.217 And welcome to Expressions Q126 00:00:49.217 -- 00:00:54.308 webcast. I'm Ben Fransen, CEO of Expression Biotech, and with me today 00:00:54.308 -- 00:00:57.150 is our CFO, Keith Alexander. 00:00:57.150 -- 00:01:01.775 I'll first walk through the key development across our pipeline and platform activities 00:01:01.775 -- 00:01:06.840 during the first quarter, and particularly progress in our HER2 breast cancer 00:01:06.840 -- 00:01:08.281 immunotherapy 00:01:08.281 -- 00:01:12.805 project, as well as our grant-funded infectious diseases programs before Keith takes 00:01:12.805 -- 00:01:14.247 over 00:01:14.247 -- 00:01:17.368 and goes through the financial results. 00:01:18.044 -- 00:01:20.228 And of co...